Please assess the completion status of the following clinical trial:

Trial Title: Dysregulated Tyrosine Kinase Signaling in Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have newly diagnosed or relapsed leukemia.~* Patients must sign an informed consent.~* Patients will not be excluded if they are receiving chemotherapy.~* Patients with CML, AML, ALL, T/NK leukemia, myelodysplasia, or myeloproliferative disorders will be eligible.~* Patients must be =\> 18 years of age.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).